PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Benzenesulfonates
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Nitrogen Mustard Compounds
  • Pyridines

abstract

  • PR-104 plus sorafenib was poorly tolerated in patients with advanced HCC, possibly because of compromised clearance of PR-104A in this patient population. Thrombocytopenia mainly and neutropenia were the most clinically significant toxicities and led to discontinuation of the study. PR-104 plus sorafenib is unlikely to be suitable for development in this setting.

publication date

  • August 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-011-1671-3

PubMed ID

  • 21594722

Additional Document Info

start page

  • 539

end page

  • 45

volume

  • 68

number

  • 2